C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib

BACKGROUND AND AIM: Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS One
Asıl Yazarlar: Hayashi, Tsuguru, Shibata, Michihiko, Oe, Shinji, Miyagawa, Koichiro, Honma, Yuichi, Harada, Masaru
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2020
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755182/
https://ncbi.nlm.nih.gov/pubmed/33351844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0244370
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller